Sanara MedTech Inc. SMTI Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by Sanara MedTech Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Sanara MedTech Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sanara MedTech Inc.'s total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sanara MedTech Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Sanara MedTech Inc. (SMTI) reported total cash, cash equivalents, and restricted cash (inclusive) of $13.59M in Q1 2026.
- How has Sanara MedTech Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- Sanara MedTech Inc.'s total cash, cash equivalents, and restricted cash (inclusive) decreased by 34.3% year-over-year, from $20.69M to $13.59M.
- What is the long-term trend for Sanara MedTech Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Over 5 years (2020 to 2025), Sanara MedTech Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a 105.2% compound annual growth rate (CAGR), from $455.37K to $16.58M.
- What does total cash, cash equivalents, and restricted cash (inclusive) mean?
- This represents the aggregate of all cash, highly liquid cash equivalents, and restricted cash held by the company, including amounts associated with discontinued operations. It provides a comprehensive view of the company's immediate liquidity and financial flexibility. This metric is critical for evaluating the company's ability to meet short-term obligations and fund ongoing operations.